Journal Watch · Clinical Cancer Research · 2026
Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors.
Alternative strategies to enhance the immune response in epNET are needed.
TL;DR
Alternative strategies to enhance the immune response in epNET are needed.
Key findings
- The median PFS was 5.6 months (95% confidence interval, 3.5-9.9).
- Grade 3 toxicities attributed to the combination included tumor lysis (n = 1, 5%), elevated transaminases (n = 1, 5%), and fatigue (n = 2, 10%).
- Immune and angiogenic proteomic profiles demonstrated trends associated with longer time on therapy.<h4>Conclusions</h4>Cabozantinib and nivolumab were associated with limited response in patients with epNET.
- Alternative strategies to enhance the immune response in epNET are needed.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Using a Simon two-stage design, 19 patients were enrolled in the first stage. Secondary objectives included ORR by immune-related RECIST, PFS, and safety. Exploratory objectives included correlation between immune and angiogenic proteomic profile and clinical outcomes.<h4>Results</h4>Eighteen of the 19 enrolled patients were evaluable for response. Best response was partial response in one (5%), stable disease in 16 (90%), and progressive disease in one patient (5%). The ORR did not meet goal for the first stage, so enrollment was terminated.
Full abstract (original)
Background: <h4>Purpose</h4>Cabozantinib, a multi-kinase inhibitor, improves progression-free survival (PFS) in patients with advanced extrapancreatic neuroendocrine tumors (epNET). Cabozantinib alters the tumor microenvironment to be more permissive to immune cells by reducing the presence of regulatory T cells and CD14+ monocytes. This trial investigated the efficacy and safety of cabozantinib in combination with nivolumab in patients with advanced epNET.<h4>Patients and methods</h4>This was an open-label, single-arm, phase II trial, which enrolled patients with advanced epNET. Patients received nivolumab 240 mg i.v. on days 1 and 15 and cabozantinib 40 mg orally once daily on a 28-day cycle. The primary endpoint was objective response rate (ORR) by RECIST v1.1.
What they did: Using a Simon two-stage design, 19 patients were enrolled in the first stage. Secondary objectives included ORR by immune-related RECIST, PFS, and safety. Exploratory objectives included correlation between immune and angiogenic proteomic profile and clinical outcomes.<h4>Results</h4>Eighteen of the 19 enrolled patients were evaluable for response. Best response was partial response in one (5%), stable disease in 16 (90%), and progressive disease in one patient (5%). The ORR did not meet goal for the first stage, so enrollment was terminated.
Results & conclusions: The median PFS was 5.6 months (95% confidence interval, 3.5-9.9). Grade 3 toxicities attributed to the combination included tumor lysis (n = 1, 5%), elevated transaminases (n = 1, 5%), and fatigue (n = 2, 10%). Immune and angiogenic proteomic profiles demonstrated trends associated with longer time on therapy.<h4>Conclusions</h4>Cabozantinib and nivolumab were associated with limited response in patients with epNET. Alternative strategies to enhance the immune response in epNET are needed.
Abstract © the authors / Clinical Cancer Research (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1158/1078-0432.ccr-25-2337 · PubMed 41263691.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Clinical Cancer Research study find?
Alternative strategies to enhance the immune response in epNET are needed.
What type of study is this?
It is a randomised / controlled clinical trial, published in Clinical Cancer Research in 2026. Using a Simon two-stage design, 19 patients were enrolled in the first stage.
Where can I read the original paper?
The original is at the publisher via DOI 10.1158/1078-0432.ccr-25-2337. PubMed ID: 41263691. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/phase-ii-trial-of-cabozantinib-in-combination-with-nivolumab-for-advance-252337/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides